Clinical Trial Update: Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally Advanced/Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating G250 peptide plus interleukin-2 after surgical resection of locally advanced or metastatic renal cell carcinoma was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• G250 peptide (G250 peptide)
• Interleukin-2 (interleukin-2)

Snippet

Sponsor: University of Chicago | Conditions: Metastatic Renal Cell Carcinoma | Phase 2 | Status: TERMINATED